FDA approval spurs launch of Lupin’s generic Clobex Spray
The same week Lupin received approval from the Food and Drug Administration for its generic Clobex Spray (clobetasol propionate spray, 0.05%), the company launched the drug.
Baltimore-based Lupin’s generic Clobex Spray is a treatment for moderate-to-severe plaque psoriasis that affects up to 20% body surface area in patients ages 18 years old and older.
The product had a market size of roughly $30.5 million for the 12 months ended January 2018, according to IQVIA data.
Baltimore-based Lupin’s generic Clobex Spray is a treatment for moderate-to-severe plaque psoriasis that affects up to 20% body surface area in patients ages 18 years old and older.
The product had a market size of roughly $30.5 million for the 12 months ended January 2018, according to IQVIA data.